SlideShare una empresa de Scribd logo
1 de 28
ACTIVE
PHARMACEUTICAL
INGREDIENTS
“CARVEDILOL”
VINOTHARAN NAIR(1000024)
SANGIDHA JAGATHEESAN(1000013 )
CONTENTS
 Introduction
 History
 Structure of Carvedilol
 Properties of Carvedilol
 Uses of Carvedilol
 How its‟s works ??
 Why Carvedilol is preferred ??
 Common Side Effects
 Manufacturing Process
 SHE Considerations
 Price aspect
 Market Demand Vs. Supply
INTRODUCTION
Carvedilol also known as Coreg
Used commonly in the treatment of CHF
or Congestive Heart failure or high blood
pressure
Carvedilol is a nonselective beta
blocker/alpha-1 blocker indicated in the
treatment of mild to severe congestive
heart failure (CHF)
HISTORY
Carvedilol was discovered by Robert R.
Ruffolo
The discovery and development of
carvedilol encountered an adverse
regulatory climate, skepticism by the
cardiology community and hesitance by
the company, and in the early 1990s
The fate of the drug was uncertain
 Robert R Ruffolo was President of Research and
Development for Wyeth Pharmaceuticals, and
corporate Senior Vice President of Wyeth from 2001
to 2008

Robert R Ruffolo
STRUCTURE OF “CARVEDILOL”

2D view

3D view
 The trade name of Carvedilol is known as Coreg
 This tablet is oval in shape and white colored
 It contains differing concentrations
of Carvedilol namely in 3.125, 6.25, 12.5 and 25 m
dosages.
 Molecular Formula: C 24 H 26 N 2 O 4

Carvedilol in tablet form
PROPERTIES OF “CARVEDILOL”
These active pharmaceutical ingredients can
be dissolved in water, intestinal fluids or
gastric fluids
Carvedilol should be taken with food
USES OF “CARVEDILOL”
Carvedilol is used for treating high blood
pressure and congestive heart failure.
It is also used after a heart attack to improve
the chance of survival if your heart is not
pumping well
To treat a certain type of irregular heartbeat
Carvedilol also helps to relax blood
vessels, reduces the need for oxygen in the
body, and helping the heart beat more
regularly and efficiently
HOW IT WORKS ??
Most norepinephrine reactants will activate
nerve endings, which control heart muscle
movements
Carvedilol drug works by blocking the binding
of the norepinephrine to these receptors
 This way, the heart rhythm slows down and
the pumping force of the heart muscles is also
reduced
WHY “CARVEDILOL” IS PREFERRED??
Carvedilol does not worsen existing heart
failure symptoms like some other drugs do
Compared to other drugs, which work in a
similar fashion, Carvedilol does not have
much inotropic effects or inverse agonist
effects
However, there is no scientific evidence to
support the fact that Carvedilol is more
preferred compared to other beta blocking
drugs
COMMON SIDE EFFECTS:
The most common side effects include:
Dizziness
Fatigue
Hypotension
Diarrhea
Weight gain
SIDE EFFECTS IF YOU DISCONTINUE THE
CONSUMPTION OF „CARVEDILOL‟
Sharp chest pain
Irregular heartbeat
Sometimes heart attack
MANUFACTURING PROCESS OF
“CARVEDILOL”
The manufacture of products based on small molecule Active Pharmaceutical Ingredients
(API) remains critical to global healthcare
 The manufacturing landscape is also full of
challenges and opportunities
This is due to emerging international markets
and rapidly evolving
social, economic, regulatory and
environmental expectations
SIFTING
Sift Carvedilol through , Lactose
monohydrate and Ferric Oxide
through the above sifted Carvedilol
and Lactose monohydrate it is
sifted with Ferric Oxide through
Lactose monohydrate and
Microcrystalline Cellulose.
DRY MIXING
Load the above sifted material in Rapid mixer
granulator and mix for 10 minutes with
impeller slow speed.

GRANULATING
 Add binder solution over dry mix material in a
period of 10 minutes at impeller slow speed
and mix the content in Rapid Mixer Granulator
at impeller slow speed.
DRYING
Air dry the wet mass for 10 minutes and
dry at inlet temperature to reach NMT
80°C, dry the granules till loss on drying
reaches to not more than 105°C.
SIFTING AND MILLING
Sift the dried granules and mill
retentions through multimill using 1mm
screen at medium speed and knives
forward configuration. Sifting of extra
granular Materials; Sift Silica Colloidal
Anhydrous and Magnesium Stearate.
BLENDING AND LUBRICATION
 Mix the materials of dried granules with Silica
Colloidal Anhydrous in Octagonal Blender for
15 minutes. Add Magnesium Stearate to the
above materials in Octagonal Blender for 5
minutes.
THE PROCESS
FLOWCHART
RAPID MIXER GRANULATOR
SHE Consideration
SAFETY CONSIDERATION
 Reduce direct skin contact, reduce exposure via
inhalation; and minimize the possibility of chemicals
being brought home on workers‟ clothing
 As with all potentially hazardous
exposures, protective measures should include:
engineering controls (e.g., barriers and
containments, laboratory hoods, glove boxes, and
worker isolation);
 Administrative controls; personal protective
equipment (e.g., respirators, gloves and lab coats)
 Training
HEALTH CONSIDERATION
Hazardous exposure to workers may occur
through inhalation of dust created during:
hand manipulation
operation of a tablet encapsulation machine
by performing sieving and granulation
operations
PRICE ASPECT OF THIS PROCESS
 Chronic heart failure (CHF) is now recognized as a
major and escalating public health problem.
 The costs of this syndrome, both in economic and
personal terms, are considerable.
 The prevalence of CHF is 1–2% and appears to be
increasing, in part because of ageing of the
population.
 60 tablets of carvedilol of 25mg would be $4.00
MARKET DEMAND VS. SUPPLY
 Manufacture and market Carvedilol Tablets, 3.125
mg, 6.25 mg, 12.5, and 25 mg. The Office of Generic
Drugs, U.S. Food and Drug Administration, has
determined the Ranbaxy formulations to be
bioequivalent and have the same therapeutic effect
as that of the reference listed drug Coreg®
Tablets, 3.125 mg, 6.25 mg, 12.5 mg, and 25
mg, respectively.
 Total annual market sales for Carvedilol Tablets were
$1.6 billion (IMS – MAT: June 2007).
REFERENCES
http://eurjhf.oxfordjournals.org/content/ 3/3/283.full
http://www.goodrx.com/coreg/price
http://www.aafp.org/afp/1998/1101/p1627.html
http://www.ranbaxy.com/ranbaxy -gains-us-fda-approval-tomanufacture-and-market-carvedilol-tablets-in-the-us-market
 http://en.wikipedia.org/wiki/Norepinephrine /





Más contenido relacionado

La actualidad más candente

SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:Naina Mohamed, PhD
 
SGLT2 Endocrine CME Grand Rounds Final
SGLT2 Endocrine CME Grand Rounds FinalSGLT2 Endocrine CME Grand Rounds Final
SGLT2 Endocrine CME Grand Rounds FinalShannon DeGrote
 
Jardiance (Empagliflozin Tablets)
Jardiance (Empagliflozin Tablets)Jardiance (Empagliflozin Tablets)
Jardiance (Empagliflozin Tablets)Clearsky Pharmacy
 
" Coagulant & Anticoagulants "
" Coagulant & Anticoagulants " " Coagulant & Anticoagulants "
" Coagulant & Anticoagulants " Bhavesh Amrute
 
Drug therapy of shock
Drug therapy of shockDrug therapy of shock
Drug therapy of shockajaykumarbp
 
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYSaurabh Badole
 
Losartan drug profile
Losartan drug profile Losartan drug profile
Losartan drug profile ShahzebKhan114
 
Sglt 2 inhibiors in cardiovascular diseases
Sglt 2 inhibiors in cardiovascular diseasesSglt 2 inhibiors in cardiovascular diseases
Sglt 2 inhibiors in cardiovascular diseasesYogesh Shilimkar
 
Hexgabalin pharmaceutical marketing plan - case study
Hexgabalin  pharmaceutical marketing plan - case studyHexgabalin  pharmaceutical marketing plan - case study
Hexgabalin pharmaceutical marketing plan - case studyAbdelrhman Tantawy
 
Dhruti Avlani - Bilayer Tablet
Dhruti Avlani - Bilayer TabletDhruti Avlani - Bilayer Tablet
Dhruti Avlani - Bilayer TabletDHRUTI AVLANI
 
Physiologically Based Pharmacokinetic (PBPK) modeling of Nanoparticles
Physiologically Based Pharmacokinetic (PBPK) modeling of NanoparticlesPhysiologically Based Pharmacokinetic (PBPK) modeling of Nanoparticles
Physiologically Based Pharmacokinetic (PBPK) modeling of NanoparticlesAnkit Dhaundiyal
 

La actualidad más candente (20)

Sitagliptin
SitagliptinSitagliptin
Sitagliptin
 
Glimepiride
GlimepirideGlimepiride
Glimepiride
 
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
 
Empagliflozin
EmpagliflozinEmpagliflozin
Empagliflozin
 
SGLT2 Endocrine CME Grand Rounds Final
SGLT2 Endocrine CME Grand Rounds FinalSGLT2 Endocrine CME Grand Rounds Final
SGLT2 Endocrine CME Grand Rounds Final
 
Glimepiride
GlimepirideGlimepiride
Glimepiride
 
Jardiance (Empagliflozin Tablets)
Jardiance (Empagliflozin Tablets)Jardiance (Empagliflozin Tablets)
Jardiance (Empagliflozin Tablets)
 
Dpp 4 inhibitors
Dpp 4 inhibitorsDpp 4 inhibitors
Dpp 4 inhibitors
 
" Coagulant & Anticoagulants "
" Coagulant & Anticoagulants " " Coagulant & Anticoagulants "
" Coagulant & Anticoagulants "
 
Drug therapy of shock
Drug therapy of shockDrug therapy of shock
Drug therapy of shock
 
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
 
Nebivolol
NebivololNebivolol
Nebivolol
 
Losartan drug profile
Losartan drug profile Losartan drug profile
Losartan drug profile
 
Sglt 2 inhibiors in cardiovascular diseases
Sglt 2 inhibiors in cardiovascular diseasesSglt 2 inhibiors in cardiovascular diseases
Sglt 2 inhibiors in cardiovascular diseases
 
Hexgabalin pharmaceutical marketing plan - case study
Hexgabalin  pharmaceutical marketing plan - case studyHexgabalin  pharmaceutical marketing plan - case study
Hexgabalin pharmaceutical marketing plan - case study
 
Statins
StatinsStatins
Statins
 
Losart (Losartan)
Losart (Losartan)Losart (Losartan)
Losart (Losartan)
 
Clopidogrel
ClopidogrelClopidogrel
Clopidogrel
 
Dhruti Avlani - Bilayer Tablet
Dhruti Avlani - Bilayer TabletDhruti Avlani - Bilayer Tablet
Dhruti Avlani - Bilayer Tablet
 
Physiologically Based Pharmacokinetic (PBPK) modeling of Nanoparticles
Physiologically Based Pharmacokinetic (PBPK) modeling of NanoparticlesPhysiologically Based Pharmacokinetic (PBPK) modeling of Nanoparticles
Physiologically Based Pharmacokinetic (PBPK) modeling of Nanoparticles
 

Similar a API Ingredients

DICLOFENAC.pptx
DICLOFENAC.pptxDICLOFENAC.pptx
DICLOFENAC.pptxanjaliKM13
 
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeAguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeDanielle Labreche
 
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeAguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeDanielle Labreche
 
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from EscoHospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from EscoEsco Group
 
Pharmaceutical industry and unit process
Pharmaceutical industry and unit processPharmaceutical industry and unit process
Pharmaceutical industry and unit processibtihal osman
 
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdfpharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdfAngelitaOrate1
 
Manufacture of parenteral products and troubleshooting
Manufacture of parenteral products and troubleshootingManufacture of parenteral products and troubleshooting
Manufacture of parenteral products and troubleshootingMostafaQalavand1
 
Manufacture of Parenteral Products and Troubleshooting - Part A
Manufacture of Parenteral Products and Troubleshooting - Part AManufacture of Parenteral Products and Troubleshooting - Part A
Manufacture of Parenteral Products and Troubleshooting - Part AWang Lang
 
anticoagulant.pptx
anticoagulant.pptxanticoagulant.pptx
anticoagulant.pptxRCharulatha4
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakriashivanikakria
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakriashivanikakria
 
Combination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptxCombination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptxJyotiNikale
 
Safety alerts for human medical products dialysate concentrates used in hem...
Safety alerts for human medical products   dialysate concentrates used in hem...Safety alerts for human medical products   dialysate concentrates used in hem...
Safety alerts for human medical products dialysate concentrates used in hem...Michael J. Evans
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance ANAhmed Nouri
 
Fastest-Growing Industry of Pharmaceutical.
Fastest-Growing Industry of Pharmaceutical. Fastest-Growing Industry of Pharmaceutical.
Fastest-Growing Industry of Pharmaceutical. Ajjay Kumar Gupta
 

Similar a API Ingredients (20)

Eli lilly and company
Eli lilly and companyEli lilly and company
Eli lilly and company
 
DICLOFENAC.pptx
DICLOFENAC.pptxDICLOFENAC.pptx
DICLOFENAC.pptx
 
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeAguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
 
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeAguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
 
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from EscoHospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
 
Pharmaceutical industry and unit process
Pharmaceutical industry and unit processPharmaceutical industry and unit process
Pharmaceutical industry and unit process
 
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdfpharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
 
Manufacture of parenteral products and troubleshooting
Manufacture of parenteral products and troubleshootingManufacture of parenteral products and troubleshooting
Manufacture of parenteral products and troubleshooting
 
Manufacture of Parenteral Products and Troubleshooting - Part A
Manufacture of Parenteral Products and Troubleshooting - Part AManufacture of Parenteral Products and Troubleshooting - Part A
Manufacture of Parenteral Products and Troubleshooting - Part A
 
anticoagulant.pptx
anticoagulant.pptxanticoagulant.pptx
anticoagulant.pptx
 
Oral Anticoagulation
Oral AnticoagulationOral Anticoagulation
Oral Anticoagulation
 
Development and in vitro characterization of HIV drugs combination
Development and in vitro characterization of HIV drugs combinationDevelopment and in vitro characterization of HIV drugs combination
Development and in vitro characterization of HIV drugs combination
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakria
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakria
 
Cardiotonics
CardiotonicsCardiotonics
Cardiotonics
 
Uses and side-effects of Nebivolol Hydrochloride
Uses and side-effects of Nebivolol HydrochlorideUses and side-effects of Nebivolol Hydrochloride
Uses and side-effects of Nebivolol Hydrochloride
 
Combination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptxCombination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptx
 
Safety alerts for human medical products dialysate concentrates used in hem...
Safety alerts for human medical products   dialysate concentrates used in hem...Safety alerts for human medical products   dialysate concentrates used in hem...
Safety alerts for human medical products dialysate concentrates used in hem...
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Fastest-Growing Industry of Pharmaceutical.
Fastest-Growing Industry of Pharmaceutical. Fastest-Growing Industry of Pharmaceutical.
Fastest-Growing Industry of Pharmaceutical.
 

Más de Sangidha Jagatheesan

Más de Sangidha Jagatheesan (9)

Methods to Set Goals and Achieve Them
Methods to Set Goals and Achieve ThemMethods to Set Goals and Achieve Them
Methods to Set Goals and Achieve Them
 
Thermodynamics Chapter 1 (Introduction)
Thermodynamics Chapter 1 (Introduction)Thermodynamics Chapter 1 (Introduction)
Thermodynamics Chapter 1 (Introduction)
 
Presentation 11th april
Presentation 11th aprilPresentation 11th april
Presentation 11th april
 
Etnik presentation
Etnik presentationEtnik presentation
Etnik presentation
 
Family Issues
Family IssuesFamily Issues
Family Issues
 
Paper and Pulp Industry
Paper and Pulp IndustryPaper and Pulp Industry
Paper and Pulp Industry
 
Environmental Science slides
Environmental Science slidesEnvironmental Science slides
Environmental Science slides
 
0.1 introduction to waves
0.1 introduction to waves0.1 introduction to waves
0.1 introduction to waves
 
Chapter 1 introduction to organic chemistry
Chapter 1 introduction to organic chemistryChapter 1 introduction to organic chemistry
Chapter 1 introduction to organic chemistry
 

Último

microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfChris Hunter
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfSanaAli374401
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docxPoojaSen20
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterMateoGardella
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Disha Kariya
 

Último (20)

microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 

API Ingredients

  • 2. CONTENTS  Introduction  History  Structure of Carvedilol  Properties of Carvedilol  Uses of Carvedilol  How its‟s works ??  Why Carvedilol is preferred ??  Common Side Effects  Manufacturing Process  SHE Considerations  Price aspect  Market Demand Vs. Supply
  • 3. INTRODUCTION Carvedilol also known as Coreg Used commonly in the treatment of CHF or Congestive Heart failure or high blood pressure Carvedilol is a nonselective beta blocker/alpha-1 blocker indicated in the treatment of mild to severe congestive heart failure (CHF)
  • 4. HISTORY Carvedilol was discovered by Robert R. Ruffolo The discovery and development of carvedilol encountered an adverse regulatory climate, skepticism by the cardiology community and hesitance by the company, and in the early 1990s The fate of the drug was uncertain
  • 5.  Robert R Ruffolo was President of Research and Development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth from 2001 to 2008 Robert R Ruffolo
  • 7.  The trade name of Carvedilol is known as Coreg  This tablet is oval in shape and white colored  It contains differing concentrations of Carvedilol namely in 3.125, 6.25, 12.5 and 25 m dosages.  Molecular Formula: C 24 H 26 N 2 O 4 Carvedilol in tablet form
  • 8. PROPERTIES OF “CARVEDILOL” These active pharmaceutical ingredients can be dissolved in water, intestinal fluids or gastric fluids Carvedilol should be taken with food
  • 9. USES OF “CARVEDILOL” Carvedilol is used for treating high blood pressure and congestive heart failure. It is also used after a heart attack to improve the chance of survival if your heart is not pumping well To treat a certain type of irregular heartbeat Carvedilol also helps to relax blood vessels, reduces the need for oxygen in the body, and helping the heart beat more regularly and efficiently
  • 10. HOW IT WORKS ?? Most norepinephrine reactants will activate nerve endings, which control heart muscle movements Carvedilol drug works by blocking the binding of the norepinephrine to these receptors  This way, the heart rhythm slows down and the pumping force of the heart muscles is also reduced
  • 11. WHY “CARVEDILOL” IS PREFERRED?? Carvedilol does not worsen existing heart failure symptoms like some other drugs do Compared to other drugs, which work in a similar fashion, Carvedilol does not have much inotropic effects or inverse agonist effects However, there is no scientific evidence to support the fact that Carvedilol is more preferred compared to other beta blocking drugs
  • 12. COMMON SIDE EFFECTS: The most common side effects include: Dizziness Fatigue Hypotension Diarrhea Weight gain
  • 13. SIDE EFFECTS IF YOU DISCONTINUE THE CONSUMPTION OF „CARVEDILOL‟ Sharp chest pain Irregular heartbeat Sometimes heart attack
  • 14. MANUFACTURING PROCESS OF “CARVEDILOL” The manufacture of products based on small molecule Active Pharmaceutical Ingredients (API) remains critical to global healthcare  The manufacturing landscape is also full of challenges and opportunities This is due to emerging international markets and rapidly evolving social, economic, regulatory and environmental expectations
  • 15. SIFTING Sift Carvedilol through , Lactose monohydrate and Ferric Oxide through the above sifted Carvedilol and Lactose monohydrate it is sifted with Ferric Oxide through Lactose monohydrate and Microcrystalline Cellulose.
  • 16. DRY MIXING Load the above sifted material in Rapid mixer granulator and mix for 10 minutes with impeller slow speed. GRANULATING  Add binder solution over dry mix material in a period of 10 minutes at impeller slow speed and mix the content in Rapid Mixer Granulator at impeller slow speed.
  • 17. DRYING Air dry the wet mass for 10 minutes and dry at inlet temperature to reach NMT 80°C, dry the granules till loss on drying reaches to not more than 105°C.
  • 18. SIFTING AND MILLING Sift the dried granules and mill retentions through multimill using 1mm screen at medium speed and knives forward configuration. Sifting of extra granular Materials; Sift Silica Colloidal Anhydrous and Magnesium Stearate.
  • 19. BLENDING AND LUBRICATION  Mix the materials of dried granules with Silica Colloidal Anhydrous in Octagonal Blender for 15 minutes. Add Magnesium Stearate to the above materials in Octagonal Blender for 5 minutes.
  • 23. SAFETY CONSIDERATION  Reduce direct skin contact, reduce exposure via inhalation; and minimize the possibility of chemicals being brought home on workers‟ clothing  As with all potentially hazardous exposures, protective measures should include: engineering controls (e.g., barriers and containments, laboratory hoods, glove boxes, and worker isolation);  Administrative controls; personal protective equipment (e.g., respirators, gloves and lab coats)  Training
  • 24. HEALTH CONSIDERATION Hazardous exposure to workers may occur through inhalation of dust created during: hand manipulation operation of a tablet encapsulation machine by performing sieving and granulation operations
  • 25. PRICE ASPECT OF THIS PROCESS  Chronic heart failure (CHF) is now recognized as a major and escalating public health problem.  The costs of this syndrome, both in economic and personal terms, are considerable.  The prevalence of CHF is 1–2% and appears to be increasing, in part because of ageing of the population.  60 tablets of carvedilol of 25mg would be $4.00
  • 26. MARKET DEMAND VS. SUPPLY  Manufacture and market Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5, and 25 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Coreg® Tablets, 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg, respectively.  Total annual market sales for Carvedilol Tablets were $1.6 billion (IMS – MAT: June 2007).
  • 27.